You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 24, 2024

Details for Patent: 9,421,192

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,421,192 protect, and when does it expire?

Patent 9,421,192 protects DAKLINZA and is included in one NDA.

This patent has sixty-seven patent family members in thirty-one countries.

Summary for Patent: 9,421,192

Title:	Hepatitis C virus inhibitors
Abstract:	The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
Inventor(s):	Belema; Makonen (North Haven, CT), Nguyen; Van N. (West Haven, CT)
Assignee:	Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:	14/934,538
Patent Claim Types: see list of patent claims	Use; Compound;

Drugs Protected by US Patent 9,421,192

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bristol-myers Squibb	DAKLINZA	daclatasvir dihydrochloride	TABLET;ORAL	206843-001	Jul 24, 2015		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up		Y		METHOD OF INHIBITING HEPATITIS C VIRUS WITH DAKLINZA AND AT LEAST ONE ADDITIONAL COMPOUND HAVING ANTI-HCV ACTIVITY	⤷ Sign Up
Bristol-myers Squibb	DAKLINZA	daclatasvir dihydrochloride	TABLET;ORAL	206843-001	Jul 24, 2015		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up		Y		METHOD OF INHIBITING HEPATITIS C VIRUS	⤷ Sign Up
Bristol-myers Squibb	DAKLINZA	daclatasvir dihydrochloride	TABLET;ORAL	206843-002	Jul 24, 2015		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up		Y		METHOD OF INHIBITING HEPATITIS C VIRUS WITH DAKLINZA AND AT LEAST ONE ADDITIONAL COMPOUND HAVING ANTI-HCV ACTIVITY	⤷ Sign Up
Bristol-myers Squibb	DAKLINZA	daclatasvir dihydrochloride	TABLET;ORAL	206843-002	Jul 24, 2015		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up		Y		METHOD OF INHIBITING HEPATITIS C VIRUS	⤷ Sign Up
Bristol-myers Squibb	DAKLINZA	daclatasvir dihydrochloride	TABLET;ORAL	206843-003	Apr 13, 2016		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up		Y		METHOD OF INHIBITING HEPATITIS C VIRUS WITH DAKLINZA AND AT LEAST ONE ADDITIONAL COMPOUND HAVING ANTI-HCV ACTIVITY	⤷ Sign Up
Bristol-myers Squibb	DAKLINZA	daclatasvir dihydrochloride	TABLET;ORAL	206843-003	Apr 13, 2016		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up		Y		METHOD OF INHIBITING HEPATITIS C VIRUS	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 9,421,192

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2049522	⤷ Sign Up	C300713	Netherlands	⤷ Sign Up
European Patent Office	2049522	⤷ Sign Up	CA 2015 00003	Denmark	⤷ Sign Up
European Patent Office	2049522	⤷ Sign Up	C20150003 00128	Estonia	⤷ Sign Up
European Patent Office	2049522	⤷ Sign Up	PA2015006	Lithuania	⤷ Sign Up
European Patent Office	2049522	⤷ Sign Up	92635	Luxembourg	⤷ Sign Up
European Patent Office	2049522	⤷ Sign Up	15C0007	France	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.